IP Library Granted Patent US 7,902,376
Granted Patent B2
US 7,902,376 · App. 12/321,533 · Granted Mar 8, 2011

Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,902,376
App. No.
12/321,533
Granted
Mar 8, 2011
Kind
B2
Abstract

A novel process is provided for the preparation of chiral trans-2,3-disubstituted 5-oxotetrahydropyrans of structural formula (I): wherein Ar is optionally substituted phenyl and P is a primary amine protecting group. These compounds are useful in the synthesis of dipeptidyl peptidase-IV inhibitors for the treatment of Type 2 diabetes. Also provided are useful intermediates obtained from the process.

Claims (54)

1. A process for preparing a compound of structural formula (I):

wherein Ar is phenyl optionally substituted with one to five R 1 substituents;

each R 1 is independently selected from the group consisting of:

fluorine,

chlorine,

C 1-6 alkyl, optionally substituted with one to five fluorines, and

C 1-6 alkoxy, optionally substituted with one to five fluorines;

and P represents a primary amine protecting group;

comprising the step of treating a compound of structural formula (VII) with an oxidizing agent in a suitable solvent:

2. The process of claim 1 additionally comprising the step of producing a compound of structural formula (VII):

by hydroboration of a compound of structural formula (VI) with a borane reagent followed by oxidative work-up:

3. The process of claim 2 additionally comprising the step of producing a compound of structural formula (VI):

by subjecting a compound of structural formula (V):

to rhodium- or ruthenium-catalyzed cycloisomerization conditions in a suitable organic solvent.

4. The process of claim 3 additionally comprising the step of producing a compound of structural formula (V):

by treating a compound of structural formula (III):

in a suitable organic solvent with a source of hydrogen, a base, and a Ru(η 6 -arene)-N-sulfonyl-1,2-diamine catalyst.

5. The process of claim 4 additionally comprising the step of producing a compound of structural formula (III):

by treating a compound of structural formula (II):

with a Grignard reagent of structural formula (IV):

ArMgBr or ArMgI   (IV)

in a suitable organic solvent.

6. The process of claim 5 additionally comprising the step of producing a compound of structural formula (II):

by (i) alkylating a C 1-6 alkyl N-(diphenylmethylene)glycinate with a propargyl sulfonate or propargyl halide in the presence of base followed by treatment with acid to liberate the free primary amine; (ii) reacting said liberated primary amine with a primary amine protecting reagent in the presence of base; and (iii) treating the resulting N-protected amino acid with N,O-dimethylhydroxylamine in the presence of an activating reagent in a suitable organic solvent.

7. The process of claim 6 additionally comprising the step of isolating the compound of structural formula (I).

8. The process of claim 1 wherein Ar is 2,5-difluorophenyl or 2,4,5-trifluorophenyl.

9. The process of claim 1 wherein P is t-butyloxycarbonyl.

10. The process of claim 9 wherein Ar is 2,5-difluorophenyl.

11. A process for preparing a compound of structural formula (VIII):

wherein V is selected from the group consisting of:

and R 2 and R 3 are each independent selected from the group consisting of hydrogen, C 1-3 alkyl, trifluoromethyl, 2,2,2-trifluoroethyl, and cyclopropyl;

comprising the steps of:

(a) producing a compound of structural formula (II):

by (i) alkylating a C 1-6 alkyl N-(diphenylmethylene)glycinate with a propargyl sulfonate or propargyl halide in the presence of base followed by treatment with acid to liberate the free primary amine; (ii) reacting said liberated primary amine with a primary amine protecting reagent in the presence of base; and (iii) treating the resulting N-protected amino acid with N,O-dimethylhydroxylamine in the presence of an activating reagent in a suitable organic solvent;

(b) producing a compound of structural formula (III):

by treating a compound of structural formula (II) with a Grignard reagent of structural formula (IV):

ArMgBr or ArMgI  (IV)

in a suitable organic solvent;

(c) producing a compound of structural formula (V):

by treating a compound of structural formula (III) in a suitable organic solvent with a source of hydrogen, a base, and a Ru(η 6 -arene)-N-sulfonyl-1,2-diamine catalyst;

(d) producing a compound of structural formula (VI):

by subjecting a compound of structural formula (V) to rhodium- or ruthenium-catalyzed cycloisomerization conditions in a suitable organic solvent;

(e) producing a compound of structural formula (VII):

by hydroboration of a compound of structural formula (VI) with a suitable borane reagent followed by oxidative work-up;

(f) treating a compound of structural formula (VII) with a suitable oxidizing agent in a suitable solvent to afford a compound of structural formula (I):

wherein Ar is phenyl optionally substituted with one to five R 1 substituents;

each R 1 is independently selected from the group consisting of:

fluorine,

chlorine,

C 1-6 alkyl, optionally substituted with one to five fluorines, and

C 1-6 alkoxy, optionally substituted with one to five fluorines;

and P represents a primary amine protecting group; and

(g) converting the compound of structural (I) into a compound of structural formula (VIII).

12. The process of claim 11 wherein Ar is 2,5-difluorophenyl.

Assignments (7)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2011
From: BANYU PHARMACEUTICAL CO., LTD.
To: MSD K.K.
Reel/Frame 025920/0079 →
CHANGE OF NAME Recorded Jan 26, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023845/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2009
From: XU, FENG; KIM, MARY M.; SLADICKA, TRICIA; ROSEN, JONATHAN D.; ZACUTO, MICHAEL J.
To: MERCK & CO., INC.
Reel/Frame 022269/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2009
From: KOHMURA, YOSHINORI
To: BANYU PHARMACEUTICAL CO., LTD.
Reel/Frame 022269/0282 →